E-viri
Recenzirano
-
Durand, Marlene L; Kitt, Therese M; Song, Yi; Marty, Francisco M
Clinical infectious diseases, 09/2021, Letnik: 73, Številka: 6Journal Article
This post hoc analysis of international phase III isavuconazole trials identified 50 patients (90% immunocompromised or diabetic) with invasive fungal sinusitis (88% mucormycetes, Aspergillus) who received isavuconazole as primary (n = 33) or salvage (n = 17) therapy for a median of 82 days (range, 2-882). Overall survival was 82% at day 42 and 70% at day 84.
